

SPONSORSHIP AGREEMENT

The **parties** to this agreement are:

Novo Nordisk Denmark A/S
Att.: Christian Klyver Tikkanen
Ørestads Boulevard 108, 6.
2300 København S

Danmarks Bløderforening
Kompagnistræde 22, 2.
1208 København K
Denmark

Company registration no.
CVR No. 38180045

Company registration no.
CVR No. 11802990

("Novo Nordisk")

("Recipient")

1. Purpose and nature of the sponsorship



1.1 Recipient's request and purpose

The Recipient has requested financial and/or non-financial support from Novo Nordisk for its activity EHC conference 2022 as further detailed in Attachment A.

The Recipient shall use the sponsorship only for the purpose of healthcare-related education, information, research or scientific exchange, as described in Attachment A.

1.2 Novo Nordisk's support

Novo Nordisk has decided the Recipient's request is worthy of support as part of Novo Nordisk's involvement in haemophilia community.

Novo Nordisk is one of several sponsors of the activity.

Novo Nordisk agrees to provide to the Recipient the amount of 15,688 DKK to support the request.

Novo Nordisk will not make any non-financial transfers of value.



2. Start and end dates of this agreement

This agreement shall become effective as of date of last signatory and shall remain effective until sixty (60) days after the parties have fulfilled their obligations under it.



3. Recipient's duties

3.1 Provide a tangible benefit to Novo Nordisk

In exchange for the sponsorship, the Recipient shall provide to Novo Nordisk recognition as a sponsor.

3.2 Inform Novo Nordisk of changes affecting the request

The Recipient shall inform Novo Nordisk promptly of changes affecting the nature, purpose, participants or timing of the requested support. If Novo Nordisk determines that the change affects its compliance requirements, Novo Nordisk may demand full or partial repayment of the sponsorship. The Recipient shall comply with the demand within 14 days.

3.3 Account for the activity regularly and upon completion

The Recipient regularly shall inform Novo Nordisk of the progress of the activity in writing.

3.4 Refund any unspent amounts

The Recipient shall refund to Novo Nordisk any amounts not spent for the requested purposes, as shown by the accounting and documentation.

3.5 Be responsible for care and use of sponsored items

If Novo Nordisk sponsors physical items, the Recipient is solely responsible for its own use of the sponsored items and shall assure that sponsored items are properly stored, handled and protected after delivery. Novo Nordisk is not responsible or liable for the Recipient's use of the sponsored items and is not required to carry insurance or take any other measures to protect sponsored items after delivery. Novo Nordisk provides physical items as is and without any express or implied representation or warranty of quality or performance.

3.6 Publicise Novo Nordisk as sponsor

The Recipient shall mention Novo Nordisk's name as the sponsor in publicity, advertising, announcements, articles, media releases or similar communications in relation to the supported activity.

3.7 Use Novo Nordisk branding only if approved

The Recipient may not use Novo Nordisk's logo, trademarks or other corporate identity marks or materials unless this agreement specifically permits the use or Novo Nordisk approves the use in advance in writing. Any use must comply with Novo Nordisk's Brand Manual (<https://brandportal.novonordisk.com/>).

3.8 Allow Novo Nordisk to publicise the sponsorship with Recipient's logo

The Recipient hereby permits Novo Nordisk to use the Recipient's name, logo, trademarks or other organizational identity marks or materials in publicity, advertising, announcements, articles, media releases or similar communications concerning Novo Nordisk's sponsorship.



4. General conditions

4.1 No conflict of interest

Recipient states it is not aware of any conflict of interest related to its acceptance of the sponsorship. Recipient shall inform Novo Nordisk promptly if it discovers such a conflict of interest.

4.2 Compliance with law and ethics

The Recipient acknowledges that Novo Nordisk must report the sponsorship to ENLI (Etisk Nævn for Lægemiddelindustrien) in accordance with ENLI's advertising code for advertising, etc. directed towards healthcare professionals (Kodeks vedrørende reklame m.v. for lægemidler rettet mod sundhedspersoner).

When carrying out the activity supported by the sponsorship, Recipient shall:

- obtain all licenses needed to conduct the activity,
- perform the activity in a fair and balanced manner,
- comply with all applicable laws, regulations, codes of practice, guidelines and industry standards, among others those related to bribery, corruption and unethical business practices and those governing drug promotional and advertising activities and interactions with healthcare professionals.

Recipient shall not give or receive bribes to obtain undue or improper advantage.

Novo Nordisk contract parties may securely and confidentially report suspected misconduct through the Novo Nordisk compliance hotline, www.novonordisk.com/compliancehotline . Recipient shall inform its personnel about this compliance hotline where relevant.

Novo Nordisk will not be responsible for any deviation or departure from relevant laws, standards, regulations and guidelines ("Deviations") and Recipient will indemnify, defend and hold Novo Nordisk harmless against any claim or suit brought against Novo Nordisk due to such Deviations that are not due to any act or omission by Novo Nordisk.

4.3 Parties act independently

Recipient shall incur all expenses and other financial commitments and take all other actions related to the supported activity in its own name and for its own account. By making the sponsorship, neither party assumes any right or responsibility to act on behalf of the other party.

4.4 Sponsorship is not an incentive

Novo Nordisk states and Recipient acknowledges that the sponsorship is not an incentive or reward for the past, present or future willingness of Recipient, its employees or the participants in Recipient's activities to prescribe, administer, recommend, purchase, pay for, reimburse, authorize, approve or supply, or to support in any other way, Novo Nordisk's products or services.

4.6 Parties may terminate upon breach

Either party may terminate this agreement with immediate effect upon a material breach by the other party.

4.7. Dispute resolution and applicable law

The parties shall use reasonable efforts to settle all matters in dispute amicably. Where settlement is not possible, disputes will be subject to the jurisdiction of the courts in the Recipient's location. The laws of that jurisdiction will apply to all disputed matters, to the exclusion of any rule that would refer the subject matter to another forum.

4.8. Parties' internal approvals

Each party states that the sponsorship and this agreement has been approved by an authorized person according to the organization's standard procedures.

5. Attachments



The following attachments are part of this agreement:

Attachment A: Recipient's request for support (application form, letter or email), with detailed program plan, timeline and budget

Attachment B: Invoice instructions for Recipient—for financial sponsorships only


Attachment C: Sponsorships to Health Care Organisations and Patient Organisations: required public disclosures and handling of employee data

SIGNED BY:

Date: October 28, 2022

Date: September 30, 2022


On behalf of Recipient:

DocuSigned by:

 46A0A742616D4F7...

Name: Karen Binger Holm

Title: Sekretariatsleder

On behalf of Novo Nordisk:

DocuSigned by:

 6086C4285774410...

Name: Christian Klyver Tikkanen

Title: Sr Market Access Manager & RareD Lead

Date: September 30, 2022

On behalf of Novo Nordisk:

DocuSigned by:

 D6C3B77D06B64DC...

Name: Markus Peter Hochmuth

Title: Sr. Director, MAPA & RareD BU

Attachment A to Sponsorship Agreement

Recipient's request for support (application form, letter or email)

Ansøgning om støtte til deltagelse i EHC konference 2022

Danmarks Bløderforening vil med denne ansøgning søge om støtte til at dække konferenceudgifter til EHC konferencen 2022 i København for danske hæmofilisygeplejersker og repræsentanter fra Danmarks Bløderforenings bestyrelse.

Med denne ansøgning søges om støtte til at dække deltagergebyr og ophold for syv danske hæmofilisygeplejersker og ni bestyrelsesrepræsentanter. Den samlede udgift er i alt 94.127 kr. Danmarks Bløderforening søger firmaer med produkter i det danske marked om støtte, i alt 15.688 kr. pr. firma. Vedlagt er bilag med budget.

Danmarks Bløderforening er vært, når EHC konferencen d. 7-9. oktober afholdes i København. Vi skulle i forbindelse med foreningens 50 års jubilæum have været vært for konferencen i 2020, men det blev desværre aflyst på grund af corona. Vi ser derfor meget frem til nu at kunne byde patientforeninger, sundhedsfaglige og industrirepræsentanter fra hele Europa velkommen. Der er i det internationale blødersamfund stærk solidaritet og tradition for at dele viden og erfaring om livet med blødersygdom, og vi er utrolig glade for, at det endelig kan lade sig gøre igen at mødes fysisk.

Vi har inviteret sundhedsminister Magnus Heunicke til at åbne konferencen, og der vil være oplæg om både den seneste livskvalitetsundersøgelse blandt danske bløderpatienter og om bløderappen. Se hele programmet på EHC's hjemmeside: <https://www.ehc.eu/events/2022-conference/>

Vi vil meget gerne invitere sygeplejersker ved de danske hæmofilicentre til at deltage i konferencen. Ved at deltage i EHC konferencen i København vil sygeplejerskerne både få opdateret deres faglige viden og få mulighed for at udbygge og styrke deres netværk med andre danske og europæiske hæmofilisygeplejersker.

Enhver støtte er velkommen og modtages med tak. Kontakt mig gerne, hvis der er spørgsmål til ansøgningen.

Venlig hilsen

Karen Binger Holm
Sekretariatsleder

Detailed program plan, timelines and budget



EHC Conference 2022- Programme 6-9 October 2022

Scandic Hotel, Copenhagen and online

Thursday 6 October 2022

9.00 - 17.00 **European Rare and Inhibitor Network (ERIN) Training Session**
Building an Expertise from Knowledge to Action
Open to EHC NMO volunteers only

10.00 - 17.15 **von Willebrand Platform Community Workshop**
From Guidelines and Principles to Reality
Open to EHC NMO volunteers only

18.00 - 21.30 **EHC Committees and Working Groups Networking Events (*followed by dinner*)**
Open to EHC volunteers only

Friday 7 October 2022

8.30 - 17.15 **EHC Conference**
Open to all

17.30 - 19.30 **EHC General Assembly**
Open to EHC NMOs and patients

17.30 - 19.30 **EHC Nurses Workshop on Sexual Health and Intimacy**
Open to nurses only


Saturday 8 October 2022


8.30 - 17.15 **EHC Conference**
Open to all

Sunday 9 October 2022

8.30 - 12.45 **EHC Conference**
Open to all

 EHC Conference 2022- Programme Friday 7 October <i>Scandic Hotel, Copenhagen and online</i>		
8.30 - 9.30	Quality of Life: The Danish Experience <i>Chaired by Jacob Andersen and Lone Hvittfeldt Poulsen</i> Conference Opening - Magnus Heunicke Survey on quality of life - Eva Funding Apps to track quality of life: The Danish Experience - Lone Hvittfeldt Poulsen	
9.45 - 10.45	Shared-Decision-Making and Education <i>Chaired by Jacob Andersen and Thomas Sannié</i> Shared-decision-making in practice - Kate Khair A case study in physiotherapy - Meret Timmer A patient perspective - Nicolaj Holm Ravn Faber	
10.45 - 11.15	Coffee break Meet our Exhibitors, watch the EHC Ageing and Bleeding Disorders Movie, learn about the EHC Think Tank at the EHC stand and visit the EHC exhibition 'Open a Door to a New Reality.'	
11.15 - 12.15	Mild Bleeding Disorders <i>Chaired by Julia Rauscher and Karen Fijnvandraat</i> What will future mild patients need? - Jo Eerens Addressing mild patients in the clinic - Sophie Susen The work of the European Haematology Association (EHA) on mild bleeding disorders - Francesco Rodeghiero (presenting remotely)	
12.15 - 12.45	Lunch	
12.45 - 13.30	Takeda Symposium <i>Living with a Rare Bleeding Disorder: Overcoming Mental and Physical Pain</i>	
13.45 - 14.30	Sobi Symposium <i>Informed Decision-Making: Jointly Balancing the Needs for Today and the Future</i>	
14.30 - 15.00	Coffee break Meet our Exhibitors, watch the EHC Ageing and Bleeding Disorders Movie, learn about the EHC Women and Bleeding Disorders activities at the EHC stand and visit the EHC exhibition 'Open a Door to a New Reality.'	
15.00 - 16.00	Women and Bleeding Disorders <i>Chaired by Evelyn Grimberg and Roseline d'Oirion</i> Women and Bleeding Disorders: Focus on gynaecological bleeds - Berndt Jilma Impact of gynaecological bleeds on fertility - Speaker TBC Patient perspectives - Marion Bräuer	
16.15 - 17.15	Von Willebrand Disease <i>Chaired by Sophie Susen and Eva Funding</i> Guidelines for the management of von Willebrand Disease - Manon Degenaar-Dujardin From guidelines and principles of care to reality: Implementation in clinical care - Mike Makris The importance of the comprehensive care team - Sunjeev Maini and Greta Mulders (TBC)	
17.30 - 19.30	EHC General Assembly <i>Open to EHC NMOs and patients ONLY</i>	EHC Nurses Workshop on Sexual Health and Intimacy <i>Open to nurses ONLY</i>
19.45 - 21.30	Welcome dinner <i>Scandic Hotel Copenhagen</i>	

 EHC Conference 2022- Programme Saturday 8 October <i>Scandic Hotel, Copenhagen and online</i>	
8.30 - 9.30	<i>An Update on Clinical Practices in Replacement and Non-replacement Therapies</i> <i>Chaired by Ilmar Kruis and Carmen Escuriola-Ettinghausen</i> State of the art clinical practices with replacement and non-replacement therapies - <i>Robert Klamroth (presenting remotely)</i> Patient perspectives - <i>Nathan Doyle and Eke Hulleigle</i>
9.45 - 10.45	<i>An Update on Haemophilia Gene Therapy</i> <i>Chaired by Declan Noone and Nanda Uitslager</i> Latest developments in haemophilia gene therapy - <i>Flora Peyvandi</i> Haemophilia gene therapy then and now - <i>Jack Grehan</i>
10.45 - 11.15	Coffee break Meet our Exhibitors, watch the EHC Ageing and Bleeding Disorders Movie, learn about the EHC activities on Inhibitors and Rare Bleeding Disorders at the EHC stand and visit the EHC exhibition 'Open a Door to a New Reality.'
11.15 - 12.15	<i>Maintaining Liver Health</i> <i>Chaired by Clive Smith and Evelien Mauser-Bunschoten</i> Recommendations on maintaining liver health post HCV clearance - <i>Vincenzo LaMura</i> Liver health in a world of gene therapy - <i>Johannes Oldenburg</i> Roles and (new) responsibilities for patient organisations - <i>Brian O'Mahony</i>
12.15 - 12.45	Lunch
12.45 - 13.30	<i>BioMarin Symposium</i> <i>Ageing with a Bleeding Disorder</i>
13.45 - 14.30	<i>Pfizer Symposium</i> <i>Musculoskeletal Health Assessment</i>
14.30 - 15.00	Coffee break Meet our Exhibitors, watch the EHC Ageing and Bleeding Disorders Movie, learn about the EHC Youth activities at the EHC stand and visit the EHC exhibition 'Open a Door to a New Reality.'
15.00 - 16.00	<i>Treatment Centres and Youth Debates</i> <i>Chaired by Miguel Crato and Ana Boban</i> Developing an audit for the EUHANET certification of haemophilia treatment centres - <i>Fariba Baghaei</i> Youth Debates <i>Dominik Cepik and Admir Mehic</i> <i>Anya Ganova and Conor Birkett</i>
16.15 - 17.15	<i>SLAMS</i> <i>Chaired by Declan Noone and Peter Kampmann</i> On comprehensive care <i>Joint health - Roberta Gualtierotti</i> <i>The carousel polyclinic model - Greta Mulders (TBC)</i> On treatment <i>Advances in Glanzmann Thrombasthenia - Kate Khalir</i> <i>Clinical applications of a-tamers in bleeding disorders - Berndt Jilma (presenting remotely)</i> On patient organisations <i>Pre-clinical emergency care in haemophilia - Martin Sedmina</i> <i>Accessibility of physiotherapy outside the haemophilia treatment centre - Dan McIntyre</i>
19.00 - 19.30	<i>Departure and transport</i>
19.45 - 00.00	<i>Conference dinner</i> <i>Marriott Hotel Copenhagen</i>

 EHC Conference 2022- Programme Sunday 9 October <i>Scandic Hotel, Copenhagen and online</i>	
8.30 - 9.45	<i>Reporting and monitoring mechanisms for existing and novel therapies in rare bleeding disorders</i> <i>Chaired by Amanda Bok and Marie Louise Schougaard Christiansen</i> How should novel therapies be monitored? - Mike Makris Regulatory changes for advanced medicinal products - Anja Schiel WFH World Gene Therapy Registry - Glenn Pierce Roles and responsibilities for patient organisations - Miguel Crato
10.00 - 10.45	CSL Behring Symposium Psycho-social Learnings from COVID
10.45 - 11.15	Coffee break Meet our Exhibitors, watch the EHC Ageing and Bleeding Disorders Movie, learn about the EHC von Willebrand activities at the EHC stand and visit the EHC exhibition 'Open a Door to a New Reality.'
11.15 - 12.00	Novo Nordisk Symposium Advancing Treatment and Care for all Rare Bleeding Disorders
12.15 - 12.45	Closing session <i>Chaired by Declan Noone and Jacob Andersen</i>

BUDGET EHC 2022		Euro	DKK	EURO	DKK
Sygeplejersker		Deltagerpris*		Overnatning**	
Skejby 1	3 nætter	450	3.347	510	3.793
Skejby2	3 nætter	450	3.347	510	3.793
Skejby 3	3 nætter	450	3.347	510	3.793
Riget 1	2 nætter	450	3.347	340	2.529
Riget 2	2 nætter	450	3.347	340	2.529
Riget 3	2 nætter	450	3.347	340	2.529
Riget 4	2 nætter	450	3.347	340	2.529
Bestyrelse					
Tem Folmand	3 nætter	225	1.674	510	3.793
Morten Skovhus Eriksen	3 nætter	225	1.674	510	3.793
Martin Sørensen	3 nætter	225	1.674	510	3.793
Hazel Engelsmann	3 nætter	225	1.674	510	3.793
Heidi Brandt	3 nætter	225	1.674	510	3.793
Palle Lykke Ravn	3 nætter	225	1.674	510	3.793
Daniel Straagaard Jensen	3 nætter	225	1.674	510	3.793
Dennis Jensen	3 nætter	225	1.674	510	3.793
Palle Skovby	3 nætter	225	1.674	510	3.793
Sum		5.175	38.495	7.480	55.632
I alt	Euro	12.655	KKR	94.127	

Firmaer på det danske marked søges om støtte, i alt 15.688 kr. pr. firma

* Deltagerpris inkluderer:

Adgang til konferencesessioner

Konference App

Velkomstreception og middagsbuffet fredag d. 7. oktober

Frokost fredag, lørdag og søndag

Kaffe/te i pauserne

Konferencemiddag lørdag d. 8. oktober

** Overnatning på ScandicCopenhagen, 170 Euro pr. nat

Attachment B to Sponsorship Agreement

Invoice instructions for Recipient—for financial sponsorships only

Novo Nordisk requires a complete and correct invoice from the recipient before paying the sponsorship amount.

Novo Nordisk will pay invoices only via electronic funds transfer to the Recipient's account.



INVOICE CONTENTS

Any invoice that does not meet the criteria below will be returned for correction.

Recipient's information

- ☐ Recipient's full company name and address (the company signing the Sponsorship Agreement)
- ☐ Bank account for electronic payment: account holder name, account number (IBAN), bank name and address, routing number or code (SWIFT/BIC in EU)

Invoice information

- ☐ Invoice number or reference
- ☐ Invoice date
- ☐ Specification of the account entry type (invoice, credit note, etc.)

Sponsorship information

- ☐ Quantity and nature of the sponsored activity covered by the invoice
- ☐ Date (if known) of the sponsored activity covered by the invoice
- ☐ Sponsorship amount payable and currency

Novo Nordisk information

- ☐ Novo Nordisk's full company name and address (the company signing the Sponsorship Agreement):
Novo Nordisk Denmark A/S, Ørestads Boulevard 108, 6., 2300 København S
- ☐ Novo Nordisk contact person's full name and initials: CTIK Christian Klyver Tikkanen

VAT or sales tax information (only where applicable by law)

- ☐ VAT or other tax amount payable
- ☐ VAT or other tax rate applied
- ☐ Novo Nordisk company VAT number: 38180045

Send invoices or credit notes by email with attached pdf (no paper copy) to:

Novo Nordisk Denmark A/S

CJZY@novonordisk.com with a copy to Novo Nordisk contact person

Attachment C to Sponsorship Agreement

Sponsorships to Health Care Organisations and Patient Organisations: required public disclosures and handling of employee data

Novo Nordisk, as a member of EFPIA (the European Federation of Pharmaceutical Industries and Associations), is required to make public the details of payments or in-kind transfers made to Recipient.

Novo Nordisk will publish information relating to this Sponsorship on Novo Nordisk's website (www.novonordisk.dk). According to local regulations Novo Nordisk may in addition make this Sponsorship Agreement publicly available.

The Recipient shall provide to Novo Nordisk upon request all information reasonably required for Novo Nordisk's compliance with legal and/or regulatory requirements for contracting, tracking and disclosing transfer of values (ToVs) to the Recipient.

Recipient will publish information on the Sponsorship on the Recipient's webpage. The information will include the Sponsorship amount and, if applicable, any in kind transfer, cf. the Danish Pharmaceutical Promotional Act (Reklamebekendtgørelsen) § 21. Publication must be made ensuring that support received from pharmaceutical companies is clearly separated. The information must be available on the Recipient's webpage no later than one (1) month after the Recipient received the Sponsorship. The information must be publicly available for at least two (2) years.

Novo Nordisk hereby informs the Recipient that information about the Recipient is collected, used, stored, transferred and disclosed (collectively **"Processed"**) by or on behalf of Novo Nordisk. Novo Nordisk processes information such as name, business address, contact details, nature of relationship with Novo Nordisk, tax number, unique identifier, and any ToVs from Novo Nordisk to the Recipient.

Whenever the Recipient shares with Novo Nordisk information about its employees, the Recipient shall inform the employees that their information is being shared and provide them with all information required under Article 13 and 14 of the General Data Protection Regulation, if applicable, and under other applicable data privacy laws. The Recipient shall indemnify Novo Nordisk and any affiliate of Novo Nordisk against all claims, expenses, losses and damages or liabilities arising from the Recipient's breach of its obligations to provide this information to its employees.

